Navigation Links
HedgePath Pharmaceuticals Enters into Key Collaboration with Mayne Pharma
Date:9/10/2013

TAMPA, Fla. and SAN DIEGO, Sept. 10, 2013 /PRNewswire/ -- HedgePath Pharmaceuticals, Inc. (OTCPink: HPPI) (HPPI) announced today that it has signed an exclusive Supply and License Agreement with Mayne Pharma International Pty Ltd (Mayne Pharma), a wholly owned subsidiary of Mayne Pharma Group Limited, an Australian ASX listed company, whereby HPPI will pursue clinical development of Mayne Pharma's patented formulation of the drug itraconazole, known as SUBA-Itraconazole, for treatment of a variety of cancers with a focus on seeking regulatory approvals and marketing in the United States.

The agreement represents a significant step forward for HPPI in the progression of its business plan of repurposing itraconazole as a potential treatment for cancer.  Itraconazole, in other formulations now off-patent, is already approved by the U.S. Food and Drug Administration (FDA) for human use as a treatment for fungal infections.

The agreement provides for the supply to HPPI of specially formulated capsules of SUBA-Itraconazole, manufactured by Mayne Pharma under cGMP (current good manufacturing practice) standards, for use by HPPI in its anticipated clinical trials, and for the future exclusive commercial supply following FDA approvals, if obtained. "SUBA technology" (which stands for "super bioavailability") is designed to improve the bioavailability of orally administered drugs that are poorly soluble. SUBA-Itraconazole is a patented formulation developed by Mayne Pharma, which has improved absorption and significantly reduced variability compared to generic itraconazole. These benefits provide enhancements to patients and prescribers with reduced intra- and inter-patient variability, enabling a more predictable clinical response and a reduction in the active drug quantity to deliver the required therapeutic blood levels.

HPPI and Mayne Pharma will collabo
'/>"/>

SOURCE HedgePath Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. HedgePath Pharmaceuticals, Inc. Completes Reorganization Plan with Commonwealth Biotechnologies
2. Boehringer Ingelheim Expands Investigation of Interferon-free Hepatitis C Treatment Regimens to Reach More Patient Types through Presidio Pharmaceuticals Clinical Collaboration
3. Roche and Inovio Pharmaceuticals partner on Inovios prostate cancer and hepatitis B immunotherapy products
4. UHC to Launch New Specialty Pharmacy Program for Better Continuity of Patient Care, Improved Access to Specialty Pharmaceuticals
5. DelMar Pharmaceuticals and Guangxi Wuzhou Pharmaceuticals Establish Clinical Advisory Board in China
6. Biogen Idec and Isis Pharmaceuticals Announce Strategic Collaboration to Advance Treatment of Neurological Disorders
7. Altaire Pharmaceuticals, Inc. Issues Voluntary Nationwide Recall of 9 lots of Carboxymethylcellulose Sodium 0.5% Ophthalmic Solution sold under several brands
8. SHAREHOLDER ALERT: Law Office of Brodsky & Smith, LLC Announces Investigation of Astex Pharmaceuticals, Inc.
9. Avanir Pharmaceuticals Announces Settlement of NUEDEXTA Patent Litigation with Wockhardt
10. Arena Pharmaceuticals to Present at the Bank of America Merrill Lynch Global Healthcare Conference
11. Buyout Alert -- Astex Pharmaceuticals -- Law Firm Seeks Higher Price For Shareholders
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2014)... , November 25, 2014 ... Instruments Market by Power Source (Electric, Battery, Pneumatic), ... Cables, Blade, Burr, Cart), by Application (Orthopedic, ENT, ... published by MarketsandMarkets, the global Powered Surgical Instruments Market ... $1.6 Billion in 2014 and is expected to ...
(Date:11/26/2014)... , Nov. 25, 2014 Nanomix ... on the development of mobile diagnostic tests ... in hospital and pre-hospital settings, today announced ... 13485:2003 certification.  The certification was awarded by ... the world,s leading certification bodies. ...
(Date:11/26/2014)... OAKS, Calif. and LONDON , ... ) and AstraZeneca (NYSE: AZN ) today announced ... evaluating two doses of brodalumab in more than 1,800 patients ... with both Stelara ® (ustekinumab) and placebo at week ... brodalumab weight-based analysis group were each shown to be superior ...
Breaking Medicine Technology:Powered Surgical Instruments Market Worth $2.1 Billion by 2019 2Powered Surgical Instruments Market Worth $2.1 Billion by 2019 3Powered Surgical Instruments Market Worth $2.1 Billion by 2019 4Nanomix Receives ISO 13485:2003 Certification 2Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 2Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 3Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 4Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 5Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 6Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 7Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 8Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 9Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 10
(Date:11/27/2014)... PITTSBURGH, PA (PRWEB) November 27, 2014 ... suffer the embarrassing side effects of urinary incontinence," said ... to it and developed this specialized accessory to prevent ... developed the Incontinence to absorb urine leakage. This prevents ... wearer from potential embarrassment. The pad ensures that the ...
(Date:11/27/2014)... Randy Dotinga HealthDay Reporter , ... seem pre-wired to acquire a second language, new research suggests. ... will likely gain a brain boost, the small study finds. ... learning," said study co-author Ping Li, co-director of the Center ... it,s even more interesting, Li said, that "the brain networks ...
(Date:11/27/2014)... Dennis Thompson HealthDay Reporter ... vaccine appears to be safe and produces an immune system ... to early clinical trial results reported by the U.S. National ... clinical trial for the vaccine paves the way for field-testing ... Sierra Leone as early as January, said Dr. Anthony Fauci, ...
(Date:11/27/2014)... In order to enable people to adapt to ... easy way to avoid touching a toilet seat and/or lid ... prototype of the patent-pending Toilet Tamer, a device that enables ... lid in a more sanitary manner. It avoids direct contact ... it promotes good hygiene and peace of mind. The portable ...
(Date:11/27/2014)... 2014 Jeffrey Carlini has practiced ... Charlotte area providing audits, reviews, compilations, tax preparation, ... of varying size across numerous industries. Jeff has ... all of their accounting and tax needs. , ... ProAdvisor Program. When asking Mr. Carlini about his ...
Breaking Medicine News(10 mins):Health News:Some People May Be Pre-Wired to Be Bilingual 2Health News:Some People May Be Pre-Wired to Be Bilingual 3Health News:Early Trial Promising for Ebola Vaccine 2Health News:Early Trial Promising for Ebola Vaccine 3Health News:Jeffrey Carlini becomes Intuit Proadvisor and receives QuickBooks certification 2
... the length of time spent using mobile telephones has ... (RF) radiations.// It has been proposed that a precautionary ... at present, there is no convincing scientific data to ... ,In view of the proximity between radio-frequency source ...
... and resultant facial scarring. A new study in the ... the American Society for Dermatologic Surgery//, reports that patients ... showed significant improvement of mild to severe acne scars ... as facial resurfacing, dermabrasion and chemical peels. ...
... elbow has been enjoying the spot light following ace cricketer ... However, the condition is not uncommon in the sports arena//. ... called in medical parlance, is an affliction where the outer ... a result of a specific strain, overuse or a direct ...
... blood pressure (BP) increase is one of the most ... most patients the condition, although urgent, is not an ... no guidelines on how to treat patients with acute ... cause of excessive hypertension and therefore antianxiety treatment may ...
... Researchers from Children’s Hospital of Boston have reconstructed ... The researchers used amniotic fluid for growing the ... these living tissues into lambs, while they were ... is used for altering birth defects. Undifferentiated stem ...
... yeast strains might have spawned an outbreak of disease ... British Columbia, Howard Hughes Medical Institute geneticists at Duke ... is normally restricted to the tropics and subtropics. ... in the pathogen's expansion may provide a useful model ...
Cached Medicine News:Health News:Mobile phones may influence normal brain functioning 2Health News:Tennis elbow not new among cricketers, say experts 2Health News:Anti-anxiety treatment found effective in lowering blood pressure 2Health News:Sex Played A Vital Role For Evolution Of Infectious Diseases 2
... HypercleanTM 22 fume containment system ... a one- or two-person work ... containment system comes complete ... four charcoal filters. (For replacement ...
Surgical-grade stainless steel disposable concentric needle with Trocar tip has an insulated platinum-alloy core and two attached 61-cm (24-in) lead wires. Needles sold in packages of 20....
... Rotavirus is the most common ... for 5% of pediatric visits ... children under 5 years. ImmunoSTAT! ... to rule in or rule ...
... test delivers 100% specificity and 100% ... minutes. With as many as ... follow-up, this assay provides a test ... to detection and treatment while reducing ...
Medicine Products: